



**We now offer FibroScan,[®]
the recognized standard for
non-invasive assessment of liver health**

We are pleased to announce that we now offer patients non-invasive, painless liver assessments with FibroScan[®], the first device to be FDA-cleared as an aid to management of patients with liver disease.


FibroScan[®] works by emitting a pulse of energy, which patients feel as a slight vibration on their skin. FibroScan[®] then measures the speed of this energy to rapidly determine liver stiffness and ultrasound attenuation, both of which can be used as a part of a broader evaluation of liver health.

FibroScan examinations are covered by most insurance plans.



**The FibroScan[®]
examination is
painless, quick
and easy.**

Next-generation liver care is advancing again right here...



**We now offer FibroScan[®]
a fast, non-invasive
diagnostic test for
managing patients
with liver disease**



Some of the benefits of a FibroScan® exam...

- Painless 10-minute procedure
- Examined area is 100x the size of a needle biopsy
- Consistent results
- Covered by insurance plans




How is a FibroScan® examination performed?



Patient lies comfortably, with the right arm raised behind their head. The operator applies a water-based gel to the skin and positions the probe with a slight pressure.

The results are delivered at the end of the examination in two numbers, liver stiffness and CAP. These represent the median values of 10 consecutive measurements and go through several checks to ensure quality.




The exam is painless and non-invasive. It's also easy and fast, usually taking 5 to 10 minutes.

In cases of active liver disease, the examination can be safely repeated.

Fibroscan® provides immediate results to the operator. A physician then interprets the result according to patient's history and underlying disease.

The dual-function technology of FibroScan® (VCTE™ and CAP™)* is the recognized standard for non-invasive assessment of liver disease, offering insights that may not be captured by traditional methods.

FibroScan® is FDA-cleared to quantitatively measure liver stiffness and ultrasound attenuation—providing important information for treating patients across the spectrum of liver disease. It is the reference for the non-invasive assessment of liver histology in the major international guidelines across many etiologies including HCV, NAFLD/NASH, and HBV. FibroScan® performs VCTE™ and CAP™ functions in a single examination.



*VCTE™ (Vibration-Controlled Transient Elastography) and CAP™ (Controlled Attenuation Parameter) are trademarks of Echosens, LLC.

Indications for use: The FibroScan® system is intended to provide 50Hz shear wave speed measurements and estimates of tissue stiffness as well as 3.5MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter) in internal structures of the body. FibroScan® is indicated for noninvasive measurement in the liver of 50Hz shear wave speed and estimates of stiffness as well as 3.5MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter.) The shear wave speed and stiffness, and CAP may be used as an aid to clinical management of adult patients with liver disease.

Shear wave speed and stiffness may be used as an aid to clinical management of pediatric patients with liver disease.



FDA
CLEARED

